MoonLake Immunotherapeutics announced that 24-week data from its Phase 2 MIRA trial with the Nanobody sonelokimab in moderate to severe hidradenitis suppurativa (HS), will be presented in a late breaking oral session on March 10 at 14:00 PST at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 8-12, in San Diego, California. The oral presentation titled ?Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial? will be presented by Professor Brian Kirby MD, FRCPI, Department of Dermatology, St.

Vincent?s University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland. The presentation will be held on Sunday 10 March at 14:00 PST /17:00 EST /23:00 CET during the late breaking research session 2 (S050) in room 20B.